Molly E Wickenhauser1, Raja B Khan2, Darcy Raches3, Jason M Ashford3, Kathryn M W Russell3, Kristin Lyons4, Giles W Robinson5, Amar Gajjar5, Paul Klimo6, Heather M Conklin7. 1. Department of Psychology, University of Mississippi, University, MS, USA. 2. Division of Neurology, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Rehabilitation Services, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Division of Neuro-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Department of Neurosurgery, University of Tennessee, Memphis, TN, USA. 7. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN, USA. Heather.Conklin@stjude.org.
Abstract
INTRODUCTION: Up to 34% of patients with medulloblastoma develop posterior fossa syndrome (PFS) following brain tumor resection and have increased risk of long-term neurocognitive impairments. Lack of agreement in conceptualization and diagnosis of PFS calls for improvements in diagnostic methods. The current study aimed to describe psychometric properties of a new posterior fossa syndrome questionnaire (PFSQ). METHODS: The PFSQ was informed by prior research and developed by a multidisciplinary team with subject matter expertise. Participants (N = 164; 63.4% Male; 78.7% White; Mage at diagnosis = 10.38 years, SD = 5.09, range 3-31 years) included patients with newly diagnosed medulloblastoma enrolled in the SJMB12 clinical trial. Forty-four patients (26.8%) were classified as having PFS based on attending physician's post-surgical yes/no report. A PFSQ was completed by a neurologist within 2 weeks of coming to St. Jude Children's Research Hospital for adjuvant treatment, irrespective of suspicion for PFS. RESULTS: PFSQ items ataxia (100.00%), dysmetria (95.45%), and speech/language changes (79.55%) were most sensitive. However, ataxia (26.50%) and dysmetria (46.61%) demonstrated low specificity. Speech/language changes (81.36%), mutism (95.76%), orofacial apraxia (98.29%) and irritability (96.61%) had high specificity. A principal component analysis found four components: (1) speech/language changes, (2) apraxias (including mutism), (3) motor/oromotor, and (4) emotional lability. CONCLUSIONS: The PFSQ is a dimensional diagnostic approach that can be used to improve diagnostic consistency across clinical and research groups to help accelerate understanding of PFS etiology, identify surgical correlates of risk, predict long-term impairments, and develop targeted interventions. Additional measure validation, including correlation with symptom resolution, is required.
INTRODUCTION: Up to 34% of patients with medulloblastoma develop posterior fossa syndrome (PFS) following brain tumor resection and have increased risk of long-term neurocognitive impairments. Lack of agreement in conceptualization and diagnosis of PFS calls for improvements in diagnostic methods. The current study aimed to describe psychometric properties of a new posterior fossa syndrome questionnaire (PFSQ). METHODS: The PFSQ was informed by prior research and developed by a multidisciplinary team with subject matter expertise. Participants (N = 164; 63.4% Male; 78.7% White; Mage at diagnosis = 10.38 years, SD = 5.09, range 3-31 years) included patients with newly diagnosed medulloblastoma enrolled in the SJMB12 clinical trial. Forty-four patients (26.8%) were classified as having PFS based on attending physician's post-surgical yes/no report. A PFSQ was completed by a neurologist within 2 weeks of coming to St. Jude Children's Research Hospital for adjuvant treatment, irrespective of suspicion for PFS. RESULTS: PFSQ items ataxia (100.00%), dysmetria (95.45%), and speech/language changes (79.55%) were most sensitive. However, ataxia (26.50%) and dysmetria (46.61%) demonstrated low specificity. Speech/language changes (81.36%), mutism (95.76%), orofacial apraxia (98.29%) and irritability (96.61%) had high specificity. A principal component analysis found four components: (1) speech/language changes, (2) apraxias (including mutism), (3) motor/oromotor, and (4) emotional lability. CONCLUSIONS: The PFSQ is a dimensional diagnostic approach that can be used to improve diagnostic consistency across clinical and research groups to help accelerate understanding of PFS etiology, identify surgical correlates of risk, predict long-term impairments, and develop targeted interventions. Additional measure validation, including correlation with symptom resolution, is required.
Authors: Thora Gudrunardottir; Angela T Morgan; Andrew L Lux; David A Walker; Karin S Walsh; Elizabeth M Wells; Jeffrey H Wisoff; Marianne Juhler; Jeremy D Schmahmann; Robert F Keating; Coriene Catsman-Berrevoets Journal: Childs Nerv Syst Date: 2016-05-03 Impact factor: 1.475
Authors: Cortney Wolfe-Christensen; Larry L Mullins; James G Scott; René Y McNall-Knapp Journal: Pediatr Blood Cancer Date: 2007-10-15 Impact factor: 3.167
Authors: Patricia L Robertson; Karin M Muraszko; Emiko J Holmes; Richard Sposto; Roger J Packer; Amar Gajjar; Mark S Dias; Jeffrey C Allen Journal: J Neurosurg Date: 2006-12 Impact factor: 5.115
Authors: Molly E Wickenhauser; Raja B Khan; Darcy Raches; Jason M Ashford; Giles W Robinson; Kathryn M Russell; Heather M Conklin Journal: Pediatr Neurol Date: 2019-11-29 Impact factor: 3.372
Authors: Mariam P Korah; Natia Esiashvili; Claire M Mazewski; Roger J Hudgins; Mourad Tighiouart; Anna J Janss; Frederick P Schwaibold; Ian R Crocker; Walter J Curran; Robert B Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-19 Impact factor: 7.038
Authors: Hyo Jung De Smet; Hanne Baillieux; Peggy Wackenier; Mania De Praeter; Sebastiaan Engelborghs; Philippe F Paquier; Peter P De Deyn; Peter Mariën Journal: Neuropsychology Date: 2009-11 Impact factor: 3.295
Authors: Jane E Schreiber; Shawna L Palmer; Heather M Conklin; Donald J Mabbott; Michelle A Swain; Melanie J Bonner; Mary L Chapieski; Lu Huang; Hui Zhang; Amar Gajjar Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300